The Board of Directors of Chosa Oncology AB resolves on a rights issue of units of approximately SEK 2.5 million fully covered by pre-subscription commitments


Idag, 19:55

The Board of Directors of Chosa Oncology AB resolves on a rights issue of units of approximately SEK 2.5 million fully covered by pre-subscription commitments

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

The Board of Directors of Chosa Oncology AB (“Chosa” or the “Company”) has today, supported by the authorization from the Annual General Meeting 2026, resolved on a rights issue of units (shares and warrants of series TO4), of initially approximately SEK 2.5 million before deduction of transaction-related costs (the “Rights Issue”). The Rights Issue is covered by pre-subscription commitments from the Board, management and other shareholders, with and without support from unit rights, covering 100 percent of the Rights Issue. Through the attached warrants of series TO4, the Company may, in October/November 2027, receive an additional maximum of approximately SEK 3.1 million before deduction of transaction-related costs. The net proceeds from the Rights Issue are primarily intended to fund the Company’s ongoing operations and financial runway through September 2027, support initial sales and marketing activities in the US, enable continued research collaboration with Mount Sinai, and complete the CLIA certification of Chosa’s diagnostic solution (DRP), thereby supporting the Company’s transition from clinical development to commercial establishment in the US. In order to enable further capital contributions, the Board of Directors may also, with the support of the issue authorization, resolve on an over-allotment issue of units (shares and warrants of series TO4) of a maximum of initially approximately SEK 2.5 million, if the Rights Issue is oversubscribed.

“This rights issue represents an important step in Chosa’s transition from clinical development towards commercialization. We are approaching several significant milestones, including the anticipated CLIA certification of our diagnostic solution, the initiation of commercial activities in the US and the generation of our first commercial revenues. The proceeds from the rights issue will provide us with the financial resources to continue executing our strategy, strengthen our commercial presence in the US and further build the clinical evidence supporting our technology. Importantly, the issue is fully secured through subscription commitments, providing a solid financial foundation for the next phase of the Company’s development. We believe Chosa is well positioned to address a significant unmet clinical need in cancer treatment, and this financing will enable us to take important steps towards realising the commercial potential of our technology”, says Peter Buhl Jensen, CEO of Chosa.

Summary

  • Today, 16 November 2026, the Board of Directors of Chosa resolved on the Rights Issue, amounting to initially a maximum of approximately SEK 2.5 million before deduction of transaction-related costs, supported by the authorization from the Annual General Meeting held on 27 May 2026. Shareholders registered in the share register maintained by Euroclear Nordics AB as of the record date, 24 November 2026, will receive one (1) unit right for each share held on the record date. Twenty (20) unit rights entitles the holder to subscribe for one (1) unit. One (1) unit consists of one (1) share and one (1) warrant of series TO4.
  • The subscription price amounts to SEK 0.55 per unit, hence corresponding to SEK 0.55 per share. Warrants of series TO4 are issued free of charge.
  • Upon full subscription, the Rights Issue will provide Chosa with approximately SEK 2.5 million before deduction of transaction-related costs. The net proceeds from the Rights Issue will be used to finance initial sales and marketing activities in the US, enable continued research collaboration with Mount Sinai, and complete the CLIA certification of Chosa’s diagnostic solution (DRP), thereby supporting the Company’s transition from clinical development to commercial establishment in the US.
  • Provided that the Rights Issue is fully subscribed and that all warrants of series TO4 are exercised, the Company may, in October/November 2027, receive an additional approximately SEK 3.1 million before deduction of transaction-related costs (excluding warrants of series TO4 attached to any units issued through a potential over-allotment issue).
  • The subscription period for the Rights Issue will run from and including 26 November 2026 up to and including 10 December 2026. The last day of trading in the Company’s share including the right to receive unit rights in the Rights Issue will be 20 November 2026.
  • The Rights Issue is covered by pre-subscription commitments totalling approximately SEK 2.5 million, corresponding to 100 percent of the Rights Issue.
  • The Company will publish an information document (“Information Document”) in connection with the Rights Issue, which is expected to be published on or around 25 November 2026.
  • To accommodate any potential excess demand for participation in the Rights Issue and thereby further strengthen the Company's financial position, the Board of Directors may, with the support of the issue authorization from the Annual General Meeting 2026, resolve to issue additional units (shares and warrants of series TO4) through a so-called over-allotment issue in the event that the Rights Issue is oversubscribed.

Background and motive

Chosa operates in a field characterised by a significant medical need for improved treatment decisions and outcomes for cancer patients. Through its technology and diagnostic solutions, the Company aims to help ensure that more patients receive the treatment most likely to provide clinical benefit, with the objective of improving treatment outcomes and prolonging patients’ lives.

Chosa addresses a significant and currently unmet clinical need. The Company's solution has the potential to enable greater differentiation in the immuno-oncology field, a market estimated to exceed USD 50 billion annually. The Board therefore considers the technology to offer significant commercial opportunities, particularly in light of continued advances in cancer immunotherapy and the growing need for more personalised treatment strategies.

The Company is entering a phase in which its focus is gradually shifting from clinical development and validation towards commercialisation. Over the coming quarters, the Company expects to generate its first commercial revenues. In parallel, the Company continues to establish its commercial presence in the US, further develop its clinical evidence base and ensure that the necessary regulatory and quality-related requirements are met to support broader market establishment.

To finance the above transition phase, the Company is carrying out the Rights Issue, which is intended to finance the Company's operations through September 2027.

Objectives

Over the next 6-18 months, Chosa has identified a number of important operational, clinical and commercial milestones. These include:

Q1 2027

  • Q&A session with the US Food and Drug Administration (FDA);
  • Presentation of results from the combination study conducted in collaboration with Mount Sinai (US), evaluating PD-(L)1 inhibitors in combination with chemotherapy; and
  • Peer-reviewed publication of the ETOP study.

Q2 2027

  • Expected approval of CLIA certification.

Q3 2027

  • Presentation of data at the World Conference on Lung Cancer; and
  • Poster presentation at ESMO; and
  • Generation of the Company's first commercial revenues.

H2 2028

  • Revenue for sales of +1,000 DRP tests.

Rights Issue

The Board of Directors of Chosa has today, 16 November 2026, resolved on a rights issue of units (shares and warrants of series TO4), with preferential rights for existing shareholders, based on the authorization granted from the annual general meeting 2026. The Rights Issue is estimated to provide Chosa with approximately SEK 2.5 million before transaction-related costs amounting to approximately 10 percent of the Rights Issue amount.

Shareholders registered in the share register maintained by Euroclear Nordics AB as of the record date, 24 November 2026, will receive one (1) unit right for each share held on the record date. Twenty (20) unit rights entitles the holder to subscribe for one (1) unit. Each unit consists of one (1) share and one (1) warrant of series TO4 at a subscription price of SEK 0.55 per unit, hence corresponding to SEK 0.55 per share. Warrants of series TO4 are issued free of charge.

The Company's share capital will initially, upon full subscription in the Rights Issue, increase by SEK 822,968.46 to SEK 17,282,340.72 through the issuance of 4,572,047 new shares, resulting in the total number of outstanding shares in the Company increasing from 91,440,957 shares to 96,013,004 shares. Shareholders who do not participate in the Rights Issue will, assuming that the Rights Issue is fully subscribed, have their ownership diluted by approximately 4.8 percent. Such shareholders may, however, have the opportunity to partially compensate themselves financially for this dilution by selling their unit rights.

The subscription period for the Rights Issue will run from and including 26 November 2026 up to and including 10 December 2026. The last day of trading in the Company's shares with the right to receive unit rights is 20 November 2026.

Subscription for units may also take place without the support of unit rights. In the event that all units are not subscribed for with the support of unit rights, the Board of Directors shall, within the maximum amount of the Rights Issue, resolve on allocation of units subscribed for without the support of unit rights in accordance with the following principles:

  1. firstly, allocation shall be made to those who have also subscribed for units with the support of unit rights, regardless of whether the subscriber was a shareholder on the record date, and, in the event of oversubscription, pro rata in relation to the number of unit rights exercised for subscription and, to the extent this cannot be done, by drawing of lots, and
  2. secondly, allocation shall be made to other persons who have applied to subscribe for units without the support of unit rights and, in the event of oversubscription, pro rata in relation to the number of units applied for and, to the extent this cannot be done, by drawing of lots.

Pre-subscription commitments

Chosa has entered into pre-subscription commitments with members of the Board, management and other shareholders, with and without the support of unit rights. The pre-subscription commitments cover 100 percent of the Rights Issue. No compensation is given for the pre-subscription commitments.

Warrants of series TO4

Warrants of series TO4 will be issued free of charge. One (1) warrant of series TO4 entitles the holder to subscribe for one (1) new share. The exercise price is set to SEK 0.68 per share. Warrants of series TO4 may be exercised for subscription of new shares in Chosa during the period from 21 October 2027 up to and including 4 November 2027. Upon full exercise of warrants of series TO4, the Company will receive approximately SEK 3.1 million before deduction of transaction-related costs (excluding warrants of series TO4 attached to any units potentially issued through an over-allotment issue). Warrants of series TO4 are intended to be admitted to trading on Spotlight Stock Market. The last day of trading in warrants of series TO4 is expected to be 2 November 2027.

Upon full exercise of the warrants of series TO4 (excluding warrants of series TO4 attached to any units potentially issued through an over-allotment issue), the share capital will increase by a further SEK 822,968.46 to SEK 18,105,309.18 through the issuance of 4,572,047 new shares, resulting in the total number of outstanding shares in the Company increasing from 96,013,004 shares (following the fully subscribed Rights Issue) to 100,585,051 shares, constituting a further ownership dilution of approximately 4.5 percent.

The aggregate dilution following full subscription of the Rights Issue and full exercise of the warrants of series TO4 will amount to approximately 9.3 percent. These dilution figures exclude any shares or warrants issued through a potential over-allotment issue.

The complete terms and conditions for TO4 will be available on the Company's website.

Timetable for the Rights Issue

  • Last day of trading in Chosa’s shares including the right to receive unit rights: 20 November 2026.
  • First day of trading in Chosa’s shares excluding the right to receive unit rights: 23 November 2026.
  • Record date for participation in the Rights Issue: 24 November 2026.
  • Publication of the Information Document: 25 November 2026.
  • Subscription period: 26 November-10 December 2026.
  • Trading in unit rights: 26 November-7 December 2026.
  • Trading in paid subscribed units (BTU’s): from and including 26 November 2026, until after the Rights Issue has been registered with the Swedish Companies Registration Office, which is expected to take place in the last week of December 2026. The last day of trading in BTU’s will be announced through a separate press release after completion of the Rights Issue.
  • Press release announcing the outcome of the Rights Issue: around 11 December 2026.

Information Document

An Information Document containing the complete terms and conditions of the Rights Issue is intended to be published through a separate press release on or around 25 November 2026 and will be available on the Company’s website (www.chosaoncology.com).

Over-allotment issue

To accommodate any potential excess demand for participation in the Rights Issue and thereby further strengthen the Company's financial position, the Board of Directors may, with the support of the issue authorization from the Annual General Meeting 2026, resolve to issue additional units (shares and warrants of series TO4) through a so-called over-allotment issue, as a directed issue, in the event that the Rights Issue is oversubscribed. The amount in the over-allotment issue is limited to an initial amount of approximately SEK 2.5 million, and the potential over-allotment issue will be made on terms and conditions substantially corresponding to those of the Rights Issue. The subscription price in the over-allotment issue, if carried out, must be a fair market price and must at least correspond to the subscription price in the Rights issue. Allotment in the over-allotment issue shall primarily be given to strategic and/or qualified investors who have entered into pre-subsciption commitments but have not received full allocation in the Rights Issue.

Advisors

Fredersen Advokatbyrå AB acts as legal advisor to the Company in connection with the Rights Issue. Aqurat Fondkommission AB acts as issuing agent in connection with the Rights Issue.

For further information about the Company, please contact:

Peter Buhl Jensen, CEO

Telephone: +45 21 60 89 22

Email: clas@realfiction.com peter@chosa.bio

This information constitutes information that Chosa Oncology AB is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the above contact person, on 16 November 2026 at 19:00 CET.

About CHOSA Oncology AB

CHOSA Oncology is a precision oncology company developing Platin-DRP®, a gene expression-based biomarker designed to predict response to platinum-based chemotherapy. By identifying patients most likely to benefit, CHOSA aims to improve outcomes and optimize treatment selection in cancer care.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Chosa. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for units in Chosa will only be made through the Information Document that Chosa intends to publish on or around 25 November 2026 on Chosa’s website, www.chosaoncology.com.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States of America, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares, warrants or other securities in Chosa have been registered, and no shares, warrants or other securities will be registered, under the United States Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation of any state or other jurisdiction in the United States of America and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.

This press release is distributed and directed only to persons in the United Kingdom who are (i) investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth entities and other persons to whom this press release may lawfully be communicated, falling within Article 49(2)(a)-(d) of the Order (all such persons together being referred to as “Relevant Persons”). Persons who are not Relevant Persons must not act on or rely on the information contained in this press release. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will only be engaged in with Relevant Persons. Persons distributing this communication must satisfy themselves that such distribution is lawful.

This press release may contain forward-looking statements which reflect the Company’s current view on future events and financial and operational development. Words such as “intend”, “will”, “expect”, “anticipate”, “may”, “believe”, “plan”, “estimate” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.

This information, the opinions and the forward-looking statements included in this press release are only applicable as of this date and may change without any notice thereof. Chosa does not undertake to publish any updates or amendments of forward-looking statements, future events or similar circumstances other than what is required by applicable legislation.

Läs mer på Cision

Ämnen i artikeln


CHOSA Oncology

Senast

0,50

1 dag %

−7,41%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån